Great session! With lots of hopeful collrectap cancer research for future ASCOs! Better patient outcomes and clinical guidelines for care Wonderful way to end #asco26 @ASCO

Grateful to have an incredible multidisciplinary team to be able to offer liver transplant to our patients @ChaseWehrle @CleClinicMD

What an incredible career and legacy. Rest in peace Dr. Habr Gama.

1/ASCO 2026 is days away and your feed is filling with "abstracts/presentation I'm most excited about." My pick is ...probably on nobody's list. The whole story is about one dose. Give me 90 seconds. It may worth a read.

#ASCO26 has released most abstracts. I will break down GI cancer-related abstracts to five tables: Important studies Interesting studies Important negative studies Novel agents Practice re-affirming studies Abstracts that have not been released but are eagerly anticipated: RASolute-302, EMERALD-3, CIRCULATE (AIO), Episode-3, BREAKWATER update, PUMP. Please see the tables below for the first two tables (important studies, interesting studies). More to come. @OncoAlert @jgong15 #GIcancer

Excellent Leadership opportunity at @ClevelandClinic Program Director for Thoracic Medical Oncology careercenter.asco.org/job/76… @ASCO

👀This novel study using methylation scores to identify exposures in patients with #Colorectal #Cancer finds an association with the herbicide picloram and #EOCRC- a potential new risk factor worthy of study! Picloram was introduced in the US in 1963. Congrats to authors @VHIO

Congratulations @MyriamChalabi ! So happy to see your bold, inspiring work recognized! 👏🏽👏🏽👏🏽Love the video too! 😊 Innovators in Science Award: 2026 Grand Prize Winner Myriam Chalabi youtu.be/ch_Zhvf4GJY?si=OMhm… via @YouTube

Out of press! Amivantamab (fully human, bispecific IgG1 monoclonal antibody) that targets EGFR and MET Monotherapy in Chemorefractory RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Results From OrigAMI-1, an Open-Label, Phase Ib/II Study | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JCO… @ASCO #colorectalcancer #cancer Enroll to #Origami2 (NCT06662786) and #Origami3 (NCT06750094) Vanderbilt University Medical Center

Very sad to see this. I remember Asal speaking so passionately about the need for clinical trials with the goal of extending the benefit of immunotherapy to all patients with colorectal cancer. @CathyEngMD @ctycka @FightCRC

Short term data but incredible

Phase 1/2 data re: @AACR #AACR2026 Daraxonrasib Gem/nab-paclitaxel (N=40) by Dr. Wolpin: ORR = 58% and 6M OS = 90%. RASolute 302 to be presented at @ASCO #ASCO2026. RASolute 303 is now open for 1st line. #pancreaticcancer @PanCAN @Rev_Medicine #cancer #cancerresearch @OncoAlert

Metastatic pancreatic cancer in the @ASCO plenary! Finally! Our patients are waiting

🚨🚨🚨 RASOLUTE-302 Ph3 is POSITIVE "Daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p < 0.0001)".... WOW! AMAZING news for patients with #PancreaticCancer The RAS Revolution is ON!! ir.revmed.com/news-releases/…

Congratulations @rachnatshroff ! So well deserved!

“You’re too young” is not a diagnosis. Colorectal cancer is now the leading cause of cancer death for men and women under 50. It is one of the only major cancers still increasing in incidence. This is not a future problem. This is already here. A few things that matter: • Screening works. Average-risk screening starts at 45, earlier if you have risk factors. • Symptoms in young people are real and should never be brushed off. • New rectal bleeding, constipation, diarrhea, bowel habit changes, abdominal pain, or unexplained anemia are warning signs. If symptoms are new or persistent, push for evaluation. If you’re eligible, get screened. If someone you know is being dismissed, advocate for them. wsj.com/health/healthcare/co…

As of today, the United States has officially left the World Health Organization. We’ll look back on this as a grave error. Health threats do not respect borders, and weakening global cooperation makes Americans less safe.

Congrats @cagirlinchi and @manjuggm and @colontown on this work! Great time saving option for patients. So happy I got to see you both at #ASCOGI26 !

Colorectal cancer research at #ASCOGI26: Patients are more willing than physicians to trade some survival for better quality of life—like oral-only treatment or fewer side effects. Poster by @DanaFarber’s @ThejusJay. asco.org/abstracts-presentat…

#GI26 BREAKWATER Encorafenib Cetuximab FOLFIRI met primary ORR endpoint (64.4% vs 39.2% for 1L FOLFIRI/Bev). Data immature on everything else, but I’m going to be offering it next week to one of my pts unfortunately with early recurrence after adjuvant FOLFOX. #BRAFV600E